BACKGROUND: Melanoma risk factors include fair pigmentation, multiple nevi, low DNA repair capacity, and CDKN2A or CDK4 mutations. Variants of the melanocortin-1 receptor (MC1R) gene have been associated with fair pigmentation and melanoma risk, and a polymorphism of the Agouti Signaling Protein (ASIP) gene has been associated with dark pigmentation. We examined MC1R and ASIP genotypes in relation to phenotypic characteristics, sporadic and familial melanoma risk, and melanoma thickness as an indicator of disease progression in a Mediterranean population. METHODS: We studied 267 melanoma patients and 382 control subjects from a case-control study and a family study in northeastern Italy. Host factors were assessed by physical examination, questionnaire, spectrophotometer, and minimal erythema dose measurement. MC1R was sequenced, ASIP was genotyped, and DNA repair capacity was measured by the host-cell reactivation assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression models. Effect modification of the association between MC1R and melanoma risk by phenotypic characteristics and DNA repair capacity was also assessed. All statistical tests were two-sided. RESULTS: Carrying MC1R variant alleles was associated with a two- to fourfold increase in risk of both sporadic and familial melanoma compared with carrying wild-type MC1R, particularly in individuals carrying multiple variant alleles (OR = 3.9; 95% CI = 3.3 to 4.6). This association was stronger in individuals with fewer additional risk factors (those with dark skin or few nevi). MC1R variant allele carriers were also three to four times more likely than were non-carriers to have thick melanomas. The ASIP polymorphism was not associated with pigmentation, nevi, or melanoma risk. CONCLUSIONS: MC1R was associated with melanoma risk and progression in a Mediterranean population, particularly in the absence of other strong risk factors, such as freckling or many nevi.
BACKGROUND:Melanoma risk factors include fair pigmentation, multiple nevi, low DNA repair capacity, and CDKN2A or CDK4 mutations. Variants of the melanocortin-1 receptor (MC1R) gene have been associated with fair pigmentation and melanoma risk, and a polymorphism of the Agouti Signaling Protein (ASIP) gene has been associated with dark pigmentation. We examined MC1R and ASIP genotypes in relation to phenotypic characteristics, sporadic and familial melanoma risk, and melanoma thickness as an indicator of disease progression in a Mediterranean population. METHODS: We studied 267 melanomapatients and 382 control subjects from a case-control study and a family study in northeastern Italy. Host factors were assessed by physical examination, questionnaire, spectrophotometer, and minimal erythema dose measurement. MC1R was sequenced, ASIP was genotyped, and DNA repair capacity was measured by the host-cell reactivation assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by logistic regression models. Effect modification of the association between MC1R and melanoma risk by phenotypic characteristics and DNA repair capacity was also assessed. All statistical tests were two-sided. RESULTS: Carrying MC1R variant alleles was associated with a two- to fourfold increase in risk of both sporadic and familial melanoma compared with carrying wild-type MC1R, particularly in individuals carrying multiple variant alleles (OR = 3.9; 95% CI = 3.3 to 4.6). This association was stronger in individuals with fewer additional risk factors (those with dark skin or few nevi). MC1R variant allele carriers were also three to four times more likely than were non-carriers to have thick melanomas. The ASIP polymorphism was not associated with pigmentation, nevi, or melanoma risk. CONCLUSIONS:MC1R was associated with melanoma risk and progression in a Mediterranean population, particularly in the absence of other strong risk factors, such as freckling or many nevi.
Authors: Peter A Kanetsky; Saarene Panossian; David E Elder; DuPont Guerry; Michael E Ming; Lynn Schuchter; Timothy R Rebbeck Journal: Cancer Date: 2010-05-15 Impact factor: 6.860
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Peter Kanetsky; Richard P Gallagher; Colin B Begg; Robert C Millikan; Terence Dwyer; Stefano Rosso; Loraine D Marrett; Nancy E Thomas; Marianne Berwick Journal: Cancer Causes Control Date: 2010-08-19 Impact factor: 2.506
Authors: Kevin M Brown; Stuart Macgregor; Grant W Montgomery; David W Craig; Zhen Zhen Zhao; Kelly Iyadurai; Anjali K Henders; Nils Homer; Megan J Campbell; Mitchell Stark; Shane Thomas; Helen Schmid; Elizabeth A Holland; Elizabeth M Gillanders; David L Duffy; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Dietrich A Stephan; Anne E Cust; David Whiteman; Adele Green; Håkan Olsson; Susana Puig; Paola Ghiorzo; Johan Hansson; Florence Demenais; Alisa M Goldstein; Nelleke A Gruis; David E Elder; Julia Newton Bishop; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; Nicholas G Martin; Jeffrey M Trent; Graham J Mann; Nicholas K Hayward Journal: Nat Genet Date: 2008-05-18 Impact factor: 38.330
Authors: Foteini Chatzinasiou; Christina M Lill; Katerina Kypreou; Irene Stefanaki; Vasiliki Nicolaou; George Spyrou; Evangelos Evangelou; Johannes T Roehr; Elizabeth Kodela; Andreas Katsambas; Hensin Tsao; John P A Ioannidis; Lars Bertram; Alexander J Stratigos Journal: J Natl Cancer Inst Date: 2011-06-21 Impact factor: 13.506
Authors: Milena Casula; Antonio Muggiano; Antonio Cossu; Mario Budroni; Corrado Caracò; Paolo A Ascierto; Elena Pagani; Ignazio Stanganelli; Sergio Canzanella; Mariacristina Sini; Grazia Palomba; Giuseppe Palmieri Journal: BMC Cancer Date: 2009-10-03 Impact factor: 4.430